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Recent work suggests that the dynorphin (DYN)/kappa opioid receptor (KOR) system may be a key mediator in the behavioral
effects of alcohol. The objective of the present study was to examine the ability of the KOR antagonist norbinaltorphimine (nor-
BNI) to attenuate relapse to ethanol seeking due to priming injections of the KOR agonist U50,488 at time points consistent with
KOR selectivity. Male Wistar rats were trained to self-administer a 10% ethanol solution, and then responding was extinguished.
Following extinction, rats were injected with U50,488 (0.1–10mg/kg, i.p.) or saline and were tested for the reinstatement of ethanol
seeking. Next, the ability of the nonselective opioid receptor antagonist naltrexone (0 or 3.0mg/kg, s.c.) and nor-BNI (0 or
20.0mg/kg, i.p.) to block U50,488-induced reinstatement was examined. Priming injections U50,488 reinstated responding on
the previously ethanol-associated lever. Pretreatment with naltrexone reduced the reinstatement of ethanol-seeking behavior. nor-
BNI also attenuated KOR agonist-induced reinstatement, but to a lesser extent than naltrexone, when injected 24 hours prior to
injections of U50,488, a time point that is consistent with KOR selectivity. While these results suggest that activation of KORs is a
key mechanism in the regulation of ethanol-seeking behavior, U50,488-induced reinstatement may not be fully selective for KORs.
1. Introduction
High rates of relapse following periods of abstinence are
typically experienced by many alcoholics, contributing to the
challenge of the long-term management of alcoholism. The
underlying neuropharmacological mechanisms associated
with relapse, however, are not yet fully understood. Recent
work suggests that the dynorphin (DYN)/kappa opioid recep-
tor (KOR) system may be a key mediator in the behavioral
effects of alcohol and other drugs of abuse [1] including
relapse.
Previous work has shown that KOR antagonists block
stress induced reinstatement of cocaine seeking and nico-
tine seeking in rats [2, 3]. The selective KOR antagonist
norbinaltorphimine (nor-BNI) also reverses reinstatement of
heroin seeking by the pharmacological stressor yohimbine
[4]. Additionally, activation of KORs via KOR agonists
reinstates cocaine-seeking behavior in squirrel monkeys
via corticotropin-releasing factor (CRF) and noradrenergic
mechanisms that are commonly associated with stress [5].
Taken together, these results suggest that KORs may play a
significant role in the stress-related effects of abstinence.
KORs may also regulate the reinstatement of ethanol-
seeking behavior. For example, the KOR antagonist JDTic
reduces cue-induced ethanol reinstatement when adminis-
tered 2 hours prior to testing [6, 7]. nor-BNI has also been
shown to reduce ethanol seeking in rats when administered
2 hours, but not 24 hours, prior to treatment with the KOR
agonist U50,488 [8]. Although these data demonstrate that
KOR antagonists reduce the reinstatement of ethanol-seeking
behavior, this effect appears to occur at time points when
these antagonists do not selectively bind to KORs. Previous
work has shown that KOR antagonists are most selective for
KORs at 24 hours after administration and are nonselective
opioid receptor antagonists at earlier times [9–11]. Because
these effects of KOR antagonists were found when admin-
istered less than 24 hours after injection, it is unclear if this
effect is specifically due to their blockade of KORs or to
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nonselective opioid receptor antagonism.The objective of the
present study was to further examine the mechanisms by
which priming injections of the KOR agonist U50,488 rein-
state ethanol seeking. Nonselective opioid receptor mecha-
nisms will be explored by investigating the ability of nal-
trexone, an antagonist with binding affinity for mu opioid
receptors (MORs), delta opioid receptors (DORs), and KORs
[12], to block U50,488-induced reinstatement of ethanol-
seeking behavior. In order to determine the specific role
of KORs in U50,488-induced reinstatement, the ability of
nor-BNI to reduce ethanol seeking at time points that are
consistent with KOR selectivity will also be examined.
2. Materials and Methods
2.1. Animals. Male Wistar rats (Charles River, Portage, MI;
𝑛 = 26) were used in this experiment. Body weights were
200–250 g and age was approximately 60 days at the start
of the experiments. Rats were group housed (2-3 per cage)
with food and water available ad libitum except during the
initial 3 days of ethanol self-administration training and were
weighed daily. Rats were maintained on a 12-hour light/dark
cycle (lights on at 22:00 h). Procedures met guidelines of the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals (NIH Publication number 85-23, revised
2011) andwere approved by the Institutional Animal Care and
Use Committee of Grand Valley State University.
2.2. Drugs and Injections. U50,488 ((trans)-3,4-dichloro-
N-methyl-N-[2-(1-pyrrolidinyl)-cyclo-hexyl] benzeneaceta-
mide; Tocris Biosciences, Ellisville, MO) and norbinaltor-
phimine (nor-BNI; Tocris Biosciences, Ellisville, MO) were
dissolved in 0.9% saline solution for intraperitoneal (i.p.)
injections. Naltrexone (Tocris Biosciences, Ellisville, MO)
was dissolved in 0.9% saline solution for subcutaneous (s.c.)
injections.
2.3. Ethanol Self-Administration Training. Rats were trained
to lever press for ethanol using an adapted sweetened solution
fading procedure [13], using saccharin that culminates in rats
consuming sufficient unsweetened 10% ethanol to produce
pharmacologically relevant blood alcohol levels. Standard
operant chambers (MedAssociates, St. Albans,VT) housed in
sound attenuated and ventilated cubicles were used. Syringe
pumps (Med Associates, St. Albans, VT) dispensed ethanol
into a stainless steel drinking cup mounted 4 cm above the
grid floor in the middle of one side panel. Two levers were
located 4.5 cm to either side of the drinking cup. Fluid
delivery and recording of operant respondingwere controlled
by a computer. A fixed ratio 1 (FR1) schedule of reinforcement
was used, with each response on the active lever resulting in
the delivery of 0.1mL of fluid.
At the onset of training, rats were limited to 2 h of access
to water in their home cages for 3 days only and were allowed
access to the operant boxes where responding on one lever
resulted in the delivery of a 0.2% saccharin solution. Similar
levels of water restriction have been previously shown to have
no effect on physiological and behavioral measures of stress
Table 1: Ethanol self-administration training procedure.
Time Procedure
3 days 0.2% saccharin; 1 lever (limited home cage wateraccess)
2 days 0.2% saccharin; 1 lever
2 days 2% ethanol + 0.2% saccharin; 1 lever
8 days 5% ethanol + 0.2% saccharin versus inactive; 2-leverchoice
4 days 5% ethanol versus inactive; 2-lever choice
2 days 8% ethanol + 0.2% saccharin versus inactive; 2-leverchoice
2 days 2% ethanol versus inactive; 2-lever choice
4 days 10% ethanol + 0.2% saccharin versus inactive; 2-leverchoice
16 days 10% ethanol versus inactive; 2-lever choice
[14]. Thereafter, water restriction was discontinued. Across
sessions, ethanol concentrations gradually increased from 5%
to 10%, with each concentration first presented with saccha-
rin and then presented alone. During this procedure one
lever was active, producing an ethanol/saccharin solution.
Responses on the inactive lever were recorded as ameasure of
general motor activity but had no programmed consequence.
Half of the animals received an ethanol/saccharin solution
following responses on the left lever and the other half
received the solution after a response on the right lever. Daily
training sessions were 30min in duration (Table 1).
2.4. Extinction. Responding for ethanol was extinguished
by eliminating the delivery of the ethanol solution follow-
ing responding on the ethanol-associated lever. Extinction
sessions were otherwise identical to the self-administration
sessions. Extinction sessions were conducted daily until
responding declined to ≤10% of the number of responses
maintained by ethanol self-administration for at least 3
consecutive sessions.
2.5. U50,488-Induced Reinstatement of Ethanol Seeking. Fol-
lowing extinction, rats (𝑛 = 13) were injected with priming
doses of U50,488 (0.1–10mg/kg, i.p.) or saline 10min prior
to testing for the reinstatement of ethanol seeking. Rats
were then placed in the operant chambers and reinstatement
testing occurred under extinction conditions. Tests were
conducted every 3-4 days, with rats experiencing extinction
sessions daily between test days.Doseswere administered in a
counterbalanced order using a Latin Square design (Figure 1).
2.6. Naltrexone and nor-BNI Antagonism of U50,488-Induced
Reinstatement. A separate group of rats (𝑛 = 13) were trained
to self-administer ethanol and then underwent extinction
as described. Following extinction, rats were pretreated
with naltrexone (3.0mg/kg, s.c.) or saline 30min prior to
reinstatement testing. Rats were then injected with priming
doses of U50,488 (0.1–1.0mg/kg, i.p.) or saline 10min prior
to testing. Test sessions were conducted every 3-4 days, with
rats experiencing extinction sessions daily between test days.
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Figure 1: Experimental timeline for U50,488-induced reinstatement testing. Rats (𝑛 = 13) were trained to self-administer ethanol, and then
lever pressing was extinguished. Following extinction rats were injected with U50,488 (0.1–10mg/kg, i.p.) or saline 10minutes prior to testing.
Tests were conducted every 3-4 days, with rats experiencing extinction sessions daily between test days.
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Figure 2: (a) Experimental timeline for naltrexone antagonism of U50,488-induced reinstatement. Rats (𝑛 = 13) were trained to self-
administer ethanol, and then lever pressing was extinguished. Following extinction, rats were pretreated with naltrexone (3.0mg/kg, s.c.)
or saline 30min prior to testing. Rats were then injected with U50,488 (0.1–1.0mg/kg, i.p.) or saline 10min prior to testing. Test sessions
were conducted every 3-4 days, with rats experiencing extinction sessions daily between test days. (b) Experimental timeline for nor-BNI
antagonism of U50,488-induced reinstatement. Stable self-administration levels were reestablished following the experiment described in (a)
and then extinguished. Following extinction, rats were pretreated with a single saline injection. 24 h later rats were injected with a U50,488
(0.1–1.0mg/kg, i.p.) or saline 10 minutes prior to testing. Test sessions were repeated every 3-4 days with rats experiencing extinction sessions
daily between test days. After all doses of U50,488 were tested, rats were given a single injection of nor-BNI (20mg/kg, i.p.). 24 h later, rats
were injected with U50,488 (0.1–1.0mg/kg, i.p.) or saline 10 minutes prior to testing. Test sessions were repeated every 3-4 days with rats
experiencing extinction sessions daily between test days.
The dose range of U50,488 was adjusted based on the results
of the previous experiment, and doses were administered
in a counterbalanced order using a Latin Square design
(Figure 2(a)).
After all dose combinations were tested in each rat, stable
self-administration levels were reestablished for 2 weeks and
then once again extinguished. One rat was excluded from
this phase of the experiment for failing to reestablish stable
levels of ethanol self-administration. Following extinction,
rats were pretreated with a single saline injection. The first
reinstatement test session occurred 24 h later when rats were
injected with a priming dose of U50,488 (0.1–1.0mg/kg, i.p.)
or saline 10min prior to testing. Over the next 6–8 days, test
sessions were repeated every 3-4 days with rats experiencing
extinction sessions daily between test days. Doses of U50,488
were administered in a counterbalanced order using a Latin
Square design.No additional saline injectionswere given over
this testing period. After all doses of U50,488 were tested,
rats were given a single injection of nor-BNI (20mg/kg,
i.p.). 24 h later, rats were injected with a priming dose of
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U50,488 (0.1–1.0mg/kg, i.p.) or saline 10min prior to testing.
A pretreatment time of 24 h was chosen because previous
research has shown that nor-BNI ismost selective forKORs at
24 h after administration as opposed to earlier times [9]. Over
the next 6–8 days, test sessionswere repeated as described.No
additional injections of nor-BNI were administered during
this time period because the selective KOR antagonist effects
of nor-BNI have been shown to last for up to 30 days after
initial administration [9, 11, 15] (Figure 2(b)). Saline and nor-
BNI pretreatment occurred in this order because nor-BNI has
been shown to be an irreversible antagonist [15].
2.7. Data Analysis. Data for the experiment examining the
reinstatement of ethanol seeking by U50,488 was analyzed
using a one-way repeated measures analysis of variance
(ANOVA) with U50,488 dose as the within subjects factor.
Post hoc analysis was performed using Tukey’s test to deter-
mine any significant differences between treatment condi-
tions. Data for the antagonism experiments were analyzed
using a two-way repeated measures ANOVA with naltrexone
or nor-BNI dose and U50,488 dose as the within subjects
factors. Sidak’s test for multiple comparisons was used for
post hoc analysis to determine if there were any significant
differences between saline and naltrexone or saline and nor-
BNI when rats were injected with U50,488. The alpha level
for all statistical analysis was 𝑝 < 0.05.
3. Results
Injections of U50,488 significantly increased responding on
the previously ethanol-associated lever (𝐹(3, 28) = 7.94, 𝑝 <
0.05, Figure 3) without affecting responding on the inactive
lever. Further analysis revealed that rats receiving the
0.1mg/kg dose of U50,488 respondedmore on the previously
ethanol-associated lever compared to rats injected with saline
or 10mg/kg U50,488 (𝑝 < 0.05, Tukey’s test).
There were significant main effects of U50,488 dose
(𝐹(2, 24) = 5.38, 𝑝 < 0.05) and naltrexone dose (𝐹(1, 12) =
39.21, 𝑝 < 0.0001) on responses on the previously ethanol-
associated lever, as well as a significant interaction between
U50,488 and naltrexone on ethanol-associated lever respond-
ing (𝐹(2, 24) = 7.56, 𝑝 < 0.01, Figure 4(a)). Post hoc anal-
ysis revealed that pretreatment with naltrexone significantly
decreased U50,488-induced responding on the ethanol-
associated lever (𝑝 < 0.05, Sidak’s test for multiple compar-
isons). There were no effects on responding on the inactive
lever (Figure 4(b)).
There were also significant main effects of U50,488 dose
(𝐹(2, 22) = 7.75, 𝑝 < 0.01) and nor-BNI dose (𝐹(1, 11) =
13.73, 𝑝 < 0.01) on ethanol-associated lever responding.
Although not statistically significant, there was a trend
towards an interaction between nor-BNI and U50,488 on
lever responses for the previously ethanol-associated lever
(𝐹(2, 22) = 2.44, 𝑝 = 0.10, Figure 5(a)). Post hoc analy-
sis demonstrated that pretreatment with nor-BNI led to a
significant decrease in U50,488-induced responding on the
ethanol-associated lever (𝑝 < 0.05, Sidak’s test for multiple
comparisons). Inactive lever responses were not affected by
any treatment (Figure 5(b)).
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Figure 3: U50,488 reinstates ethanol-seeking behavior. Rats (𝑛 =
13) were trained to self-administer a 10% ethanol solution using
standard operant procedures, and then lever pressing for ethanol
was subsequently extinguished. Responding on an inactive lever
was measured as an indication of general motor activity. Following
extinction, rats received priming injections of U50,488 (0–10mg/kg,
i.p.) and were tested for reinstatement of responding on the previ-
ously ethanol-associated lever. Tests were conducted every 3-4 days,
with rats experiencing extinction sessions daily between test days.
Data are expressed as the mean number of lever responses ± SEM
during ethanol self-administration sessions. ∗𝑝 < 0.05 compared
to self-administration, extinction, and 10.0mg/kg U-50,488 groups,
Tukey’s test.
4. Discussion
The present experiments found that U50,488 reinstates
ethanol seeking in rats previously trained to self-administer
ethanol. When considered with previous research regarding
the role of the KOR/DYN system in enhanced ethanol self-
administration [16–18] and cue-induced reinstatement [6, 7],
these results further support the hypothesis that direct acti-
vation of KORs plays a significant role in ethanol reinstate-
ment. Furthermore, nor-BNI attenuated the reinstatement of
ethanol seeking following priming injections of U50,488 at
time points consistent with KOR selectivity. However, the
magnitude of this effect was lesser than that found when rats
were pretreated with naltrexone, suggesting that other opioid
receptors may also facilitate the effects of U50,488 on ethanol
seeking. While these findings suggest that KORs are involved
in mediating KOR agonist-induced reinstatement, this effect
may not be selective to KOR activation.
The current experiments found that the KOR antag-
onist nor-BNI reverses U50,488 induced reinstatement of
responding on the previously ethanol-associated lever at time
points consistent with selective KOR antagonism. Although
this finding parallels recent work demonstrating that KOR
antagonists have the ability to attenuate the reinstatement
of ethanol seeking, this effect was previously found at time
Journal of Addiction 5
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Figure 4: (a) Naltrexone blocks U50,488-induced reinstatement of ethanol seeking. Rats (𝑛 = 13) were trained to self-administer a 10%
ethanol solution using standard operant procedures, and then lever pressing for ethanol was subsequently extinguished. Following extinction,
rats were pretreated with naltrexone (0 or 3.0mg/kg, s.c.) 30min prior to reinstatement testing. Prior to testing, rats received priming
injections of U50,488 (0–1.0mg/kg, i.p.) and were tested for reinstatement of responding on the previously ethanol-associated lever. Tests
were conducted every 3-4 days, with rats experiencing extinction sessions daily between test days. Data are expressed as the mean number
of lever responses ± SEM during ethanol self-administration sessions. ∗𝑝 < 0.05 compared to saline-injected rats receiving the same dose of
U50,488, Sidak’s test for multiple comparisons. (b) Responding on an inactive lever was measured as an indication of general motor activity.
No effects on inactive lever responding were observed.
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Figure 5: (a) nor-BNI attenuates U50,488-induced reinstatement of ethanol seeking. Rats (𝑛 = 12) were trained to self-administer a 10%
ethanol solution using standard operant procedures, and then lever pressing for ethanol was subsequently extinguished. Following extinction,
rats were pretreated with saline 24 h prior to reinstatement testing. Prior to testing, rats received priming injections of U50,488 (0–1.0mg/kg,
i.p.) and were tested for reinstatement of responding on the previously ethanol-associated lever. Over the next 6–8 days, test sessions were
repeated every 3-4 days with rats experiencing extinction sessions daily between test days, and doses of U50,488 were given in an irregular
order. After all doses of U50,488 were tested, rats were injected with the KOR antagonist nor-BNI (20mg/kg, i.p.). 24 h later, rats were injected
with a priming dose of U50,488 (0.1–1.0mg/kg, i.p.) or saline prior to testing. Over the next 6–8 days, test sessions were repeated as described.
Data are expressed as the mean number of lever responses ± SEM during ethanol self-administration sessions. ∗𝑝 < 0.05 compared to saline-
injected rats receiving the same dose of U50,488, Sidak’s test for multiple comparisons. (b) Responding on an inactive lever was measured as
an indication of general motor activity. No effects on inactive lever responding were observed.
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points that may not be consistent with KOR selectivity [6–
8]. For example, previous work has found that 10mg/kg nor-
BNI attenuated U50,488-induced reinstatement of ethanol
seeking when administered 2 hours prior to reinstatement
testing, but not when given 24 hours prior [8]. However, nor-
BNI does not appear to act as a selective KOR antagonist until
24 hours after administration and is a nonselective opioid
receptor antagonist at earlier times [9–11]. In contrast, the
present study found that a single injection of 20mg/kg nor-
BNI attenuated ethanol seeking when administered 24 hours
prior to reinstatement testing and that this effect lasted for
up to 8 days. This time course is also consistent with the
long-lasting ability of KOR antagonists to block the effects
of KOR agonists, but not the effects of nonselective opioid
agonists [9–11, 15]. One explanation for this discrepancy
is the difference in doses of nor-BNI administered. The
findings of Funk et al. [8] are consistent with a previous
study which found that injections of 10mg/kg nor-BNI did
not reverse KOR agonist-induced reinstatement of cocaine
seeking in squirrelmonkeys [5]. However, previous data from
our laboratory has shown that U50,488 induced anxiety-like
behavior is reduced in the elevated plus maze when rats are
injected with 20mg/kg nor-BNI, but not 10mg/kg nor-BNI,
24 hours prior to testing [19]. It appears that higher doses of
nor-BNI may be required to block the behavioral effects of
U50,488 at time points more consistent with KOR selectivity.
Previouswork has shown that KOR agonist-induced rein-
statement of cocaine-seeking behavior in squirrel monkeys is
reversed by naltrexone [5], and the results of the present study
extend this finding to ethanol seeking. The ability of naltrex-
one to prevent reinstatement following injections of U50,488
demonstrates that MORs and DORs may also play a signifi-
cant role in continued drug seeking following administration
of KOR agonists. This result is consistent with previous
findings demonstrating that naltrexone attenuates ethanol
priming-induced [20] and cue-induced reinstatement [21,
22]. It should also be noted that naltrexone reduced ethanol
seeking to a greater extent compared to nor-BNI. Previous
work has shown that naltrexone may be more effective than
nor-BNI in blocking the KOR agonist-induced drug seeking
[5], motor suppression [23], and antinociception [24]. When
considered with these previous results, the findings of the
current study suggest that although KORs play a key role
in regulating KOR-agonist-induced reinstatement, persistent
ethanol-seeking behavior following U50,488 administration
may not be selectively mediated by KORs.
One hypothesis is that the KOR/DYN system may work
in conjunction with other neurotransmitter systems to reg-
ulate relapse. For example, type 1 corticotropin-releasing
factor (CRF
1
) receptor antagonist CP 154,526 and the 𝛼
2
adrenoceptor agonist clonidine significantly attenuate KOR
agonist priming-induced reinstatement of drug seeking [5],
indicating that this finding is likely due to an interaction
between the KOR/DYN system and CRF and noradrener-
gic systems. Further supporting this hypothesis, U50,488-
induced reinstatement of ethanol seeking is attenuated by
the CRF
1
receptor antagonist antalarmin, and nor-BNI
reduces reinstatement via priming injection of yohimbine,
an 𝛼
2
adrenoceptor antagonist [8]. DYN and CRF appear to
interact in various regions of the brain [25–27] and stimulate
the hypothalamic-pituitary-adrenal axis in rodents [28] and
humans [29], which is primarily regulated by CRF release in
the hypothalamus [30]. With regard to noradrenergic inter-
actions, kappa opioids have been shown to enhance nore-
pinephrine turnover in the paraventricular nucleus of the
hypothalamus [28], increase norepinephrine metabolism in
the brain stem and cortex [31], and stimulate norepinephrine
release in the hippocampus [32]. Taken together with these
interactions observed between the DYN/KOR system and
other stress-related neurotransmitter systems, the present
study suggests that U50,488 may also work in conjunction
with other stress-related systems to reinstate ethanol seeking.
Although U50,488 led to a significant increase in
responding on the previously ethanol-associated lever,
response rates during reinstatement testing were less
pronounced when compared to those observed during
ethanol self-administration training. However, this lower rate
of responding is consistent with previous work examining
KOR agonist-induced reinstatement of drug seeking [5] and
may be due, in part, to the motor-suppressive effects of KOR
agonists. In the current study, only the 0.1 and 1.0mg/kg
doses of U50,488 led to an increase in responding on the
ethanol-associated lever. Rats injected with the 10mg/kg
dose of U50,488 showed response levels similar to those
seen during extinction and in rats injected with saline,
suggesting that this highest dose may have led to general
motor suppression. Previous research has found that U50,488
decreases the number of total arm entries, which is thought
to be an index of locomotor activity [33], in rats examined
in the elevated plus maze [19, 34]. U50,488 has also been
shown to decrease operant response rates [35]. In the current
study, U50,488 injections led to an increase in responding
on the previously ethanol-associated lever despite these
motor-suppressive effects, suggesting that stimulation of
KORs plays a significant role in the reinstatement of ethanol
seeking.
The current study demonstrated that the KOR agonist,
U50,488, increased responding on the previously ethanol-
associated lever following extinction, an effect attenuated by
nor-BNI at time points consistent with KOR selectivity.These
results suggest that KORs are a key mechanism in the rein-
statement of ethanol seeking. However, this effect occurred to
a lesser degree when compared to naltrexone, indicating that
U50,488 may also interact with other neurochemical systems
to reinstate ethanol-seeking behavior. When considered with
previous findings demonstrating that KOR agonists interact
with stress-related systems to reinstate drug seeking [5, 8], it
appears that U50,488 may act as a pharmacological stressor
to induce persistent ethanol seeking.
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